Drug intelligence / Profile preview

EPH-101

Development stage: Preclinical
Lead developer: Alcyone Therapeutics
Modality: Small Molecules

Overview

EPH-101 is a proprietary small molecule drug developed by Alcyone Therapeutics. It belongs to the "Efralex" class of compounds and specifically targets the EphA4 receptor, which is implicated as a common link in multiple types of neurodegenerative diseases. The mechanism of action involves modulation or inhibition of EphA4 signaling, which has been associated with neuroprotection and potential disease-modifying effects in various neurodegenerative conditions[1].

Targets

EPHA4

Beyond the preview

Go deeper on EPH-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPH-101.

Explore the full profile